Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Bret Petersen

Gastroenterology Rochester, MN Medical Doctor

NPI 1124006242 CMS profile 1135485

200 1St St Sw, Rochester, MN 55905

Open in the dashboard

General payments

$103,191

89 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$367,355 paid to institutions, not to them · program years 2019–2023

Through program year 2024, Bret Petersen of Rochester, MN is reported in the CMS Open Payments database as having received $103,191 across 89 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $367,355 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $20,254 11
2023 General $15,752 22
2022 General $688 6
2021 General $11,809 6
2020 General $30,318 16
2019 General $24,372 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bret Petersen
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Bret Petersen were reported at $0. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Bret Petersen Gastroenterology median Middle half National median
2019 $24,372 $417 $126–$1,100 $163
2020 $30,318 $224 $74–$624 $114
2021 $11,809 $352 $106–$1,054 $132
2022 $688 $448 $129–$1,270 $149
2023 $15,752 $533 $150–$1,390 $160
2024 $20,254 $605 $160–$1,606 $164
2025 $0 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Olympus Corporation of the Americas $68,414 58 payments
  2. Boston Scientific Corporation $12,419 18 payments
  3. PENTAX of America, Inc. $10,488 5 payments
  4. Ambu A/S $7,371 1 payment
  5. Olympus America Inc. $2,893 4 payments
  6. Pfizer Inc. $1,200 1 payment
  7. FUJIFILM Medical Systems USA, Inc. $210 1 payment
  8. Medtronic, Inc. $197 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Consulting Fee $77,762 30 payments
  2. Travel and Lodging $21,831 27 payments
  3. Food and Beverage $2,398 31 payments
  4. Honoraria $1,200 1 payment
Products named General payments · program years 2019–2024
  1. EVIS EXERA III DUODENOVIDEOSCOPE $20,949 25 payments
  2. SPYGLASS $11,865 11 payments
  3. EVIS EXERA II ULTRASOUND GASTROVIDEOSCOPE $4,888 5 payments
  4. EVIS EXERA lll COLONOVIDEOSCOPE $4,888 5 payments
  5. EVIS EXERA III GASTROINTESTINAL VIDEOSCOPE $4,888 5 payments
  6. EVIS EXERA III BRONCHOVIDEOSCOPE $4,888 5 payments
  7. C.A.P. HD Duodenoscope $4,465 4 payments
  8. Single Use Electrosurgical Knife KD-655 $249 2 payments
  9. EndoClot SIS $249 2 payments
  10. FUJIFILM $210 1 payment
  11. Other $1,132 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

27

Median for Gastroenterology: 569

Drug cost

$87

Median for Gastroenterology: $104,976

Branded share of claims

40.7%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 11 $66
Levofloxacin Generic 16 $21

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$59,892

Medicare's payments for the services billed

Medicare patients

193

Average age 71

Services billed

447

101 women, 92 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 74%
Chronic kidney disease 38%
Arthritis 36%
Diabetes 35%
Ischemic heart disease 30%
Depression 30%
Heart failure 24%
Cancer 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

89 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Minnesota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record